LLY
NVO
The weight-loss sequel nobody can ignore
Eli Lilly just dropped fresh late-stage data showing its obesity franchise can do more than help people lose weight — it can help them keep it off. In the SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN studies, patients who switched from higher-dose injectable incretin therapies to Foundayo or lower-dose Zepbound held onto most of their weight loss.
Why this matters for your portfolio
That’s a big deal because the obesity race has basically become the pharma version of a streaming war: everyone wants the sticky subscriber, not just the flashy first episode. If patients can stay on Lilly’s drugs and maintain results, that strengthens the case that the company’s weight-loss franchise has staying power, pricing power, and maybe a long runway beyond the current hype cycle.
The fine print, minus the snooze button
- In SURMOUNT-MAINTAIN, both maintenance-dose Zepbound and a reduced 5 mg dose hit the primary and key secondary endpoints.
- Patients who stayed on the maximum tolerated dose kept all their prior weight loss.
- Patients switched to 5 mg regained an average of 5.6 kilograms, but still maintained most of the benefit.
- In ATTAIN-MAINTAIN, people who moved from Novo Nordisk’s Wegovy to Foundayo regained just 0.9 kilograms by week 52, while those switching from Zepbound regained about 5 kilograms.
Big picture
Lilly’s obesity story is starting to look less like a single blockbuster and more like a franchise with sequels, spin-offs, and maybe a prequel or two. Add in continued revenue growth from Mounjaro and Zepbound, and you’ve got a company that still looks very much like the heavyweight in this heavyweight fight.